公开(公告)号：US20160250307A1

公开(公告)日：2016-09-01

申请号：US14975952

申请日：2015-12-21

申请人： Immatics Biotechnologies GmbH

发明人： Toni Weinschenk ,  Andrea Mahr ,  Jens Fritsche ,  Phillip Mueller ,  Anita Wiebe ,  Sara Kutscher

IPC分类号： A61K39/00 ,  C12N15/115 ,  G01N33/68 ,  C07K16/18 ,  A61K35/17 ,  C12N5/0783

CPC分类号： A61K39/0011 ,  A61K35/17 ,  A61K38/04 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/5158 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/18 ,  C07K2317/70 ,  C07K2319/40 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12N2501/998 ,  G01N33/6803

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.

摘要翻译： 本发明涉及用于免疫治疗方法的肽，蛋白质，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及单独或与其它肿瘤相关肽组合的肿瘤相关T细胞肽表位，其可以例如用作刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分或刺激T细胞 离体转移入患者。 与主要组织相容性复合物（MHC）分子结合的肽或本身的肽也可以是抗体，可溶性T细胞受体和其他结合分子的靶标。 特别地，本发明涉及可以用于引发抗肿瘤免疫应答的疫苗组合物中的几种新型肽序列及其衍生自人类肿瘤细胞的HLA I类和II类分子的变体或作为制备药物的靶标 /免疫活性化合物和细胞。

公开(公告)号：US10064926B2

公开(公告)日：2018-09-04

申请号：US14975952

申请日：2015-12-21

申请人： Immatics biotechnologies GmbH

发明人： Toni Weinschenk ,  Andrea Mahr ,  Jens Fritsche ,  Phillip Mueller ,  Anita Wiebe ,  Sara Kutscher

IPC分类号： A61K39/00 ,  C07K7/00 ,  A61K38/04 ,  C07K7/06 ,  A61K35/17 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/68 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74 ,  C07K7/08 ,  A61K35/12

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.